US 11,299,491 B2Granted

Synthesis of key intermediate of KRAS G12C inhibitor compound

AssigneeAmgen Inc.

InventorsAndrew Thomas Parsons, Brian McNeil Cochran, William Powazinik, IV, Marc Anthony Caporini

Life of this patent

Estimating the term…

Abstract

The present invention relates to an improved, efficient, scalable process to prepare intermediate compounds, such as compound 5M, having the structure useful for the synthesis of compounds that target KRAS G12C mutations, such as

Claims1

Dependent claims

A compound, wherein the compound is:

Dependencies are inferred from the claim text.

Facts

Application: 16/685,841Filed 15 Nov 2019 · us provisional application
Priority: 16 Nov 2018
Published: US 2020/0216446 A19 Jul 2020
Granted: 12 Apr 2022
Term ends: Not estimatedThe source records don’t support an estimate.

Classification7 codes

C07D 471/04
In which the condensed system contains two hetero rings: ortho-condensed systems
C07C 69/76
Esters of carboxylic acids; Esters of carbonic or haloformic acids: esters of carboxylic acids having a carboxyl group bound to a carbon atom of a…
C07C 309/24
Having sulfo groups bound to acyclic carbon atoms: of a carbon skeleton containing six-membered aromatic rings
C07B 57/00
Separation of optically-active compounds

Family

Application62/768,802Us provisional application · filed 16 Nov 2018
US 2020/0216446 A1Pre-grant publication · published 9 Jul 2020
US 11,299,491 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

Building an agent or pulling many patents? Use the API or MCP server instead of scraping pages. Get an API key

patentgrep

Loading patent…